REYKJAVIK, Iceland, June 28 /PRNewswire-FirstCall/ -- deCODE genetics today announced that it has named Birgit Stattin Norinder to its Board of Directors, effective immediately.
Ms Norinder has extensive experience in the Pharmaceutical Industry and has held senior clinical development and regulatory affairs positions in Europe and the United States at Pfizer, Astra, Glaxo and Pharmacia & Upjohn. She was CEO and Chairman of UK-based Prolifix Ltd, from 1998 until the merger of Prolifix and TopoTarget in 2002. She currently serves on the boards of several biotechnology companies including Antisoma plc, Artimplant AB, Photocure ASA, Biolipox AB, and is chairman of the board of Betagenon AB.
“We are very pleased to welcome Birgit to our board. She brings with her a wealth of experience in drug development, both in the world’s biggest pharmaceutical companies and in a range of biotechnology firms. She is ideally suited to contribute to our work as we expand our clinical development pipeline and bring our lead compounds forward to the market,” said Kari Stefansson, CEO of deCODE.
About deCODE
deCODE genetics is a global leader in applying human genetics to develop drugs for common diseases. Our population approach has enabled us to discover and target key biological pathways involved in conditions ranging from heart attack to cancer. We are turning these discoveries into new medicine to better treat and prevent many of the biggest challenges to public health. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.
Contact: deCODE genetics Edward Farmer Joy Bessenger +354 570 2819 +1 212 481 3891 info@decode.isir@decode.is
deCODE genetics
CONTACT: Edward Farmer, +354-570-2819, info@decode.is; Joy Bessenger,+1-212-481-3891, ir@decode.is, both of deCODE genetics
Web site: http://www.decode.com/
